BioCentury
ARTICLE | Company News

AZ, Sanofi deal

March 7, 2017 11:04 PM UTC

The MedImmune LLC unit of AstraZeneca and Sanofi’s Sanofi Pasteur vaccines unit partnered to develop and commercialize MedImmune's MEDI8897. AZ will continue development of MEDI8897 until its first approval and is responsible for manufacturing. Sanofi Pasteur will lead commercialization. The companies said they intend to develop MEDI8897 for passive immunization against respiratory syncytial virus (RSV) in a broad infant population. MedImmune will receive €120 million ($126.9 million) up front from Sanofi and is eligible for up to €495 million ($523.6 million) in milestones.

AZ is conducting a Phase IIb trial of MEDI8897 to prevent RSV-confirmed lower respiratory tract infections in healthy, preterm infants entering their first RSV season who are ineligible to receive Synagis palivizumab. According to ClinicalTrials.gov, data from the study are due in June 2018. The partners are planning a Phase III trial in healthy full-term and late preterm infants. MEDI8897 has Fast Track designation from FDA to prevent lower respiratory tract infection caused by RSV in infants and young children. ...

BCIQ Target Profiles

RSV F protein